NovaBay Pharmaceuticals, Inc. (NBY) Financial Statements (2024 and earlier)

Company Profile

Business Address 2000 POWELL STREET, SUITE 1150
EMERYVILLE, CA 94608
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5,3627,50411,9526,9373,1833,199
Cash and cash equivalents5,3627,50411,9526,9373,1833,199
Receivables1,9731,6681,1061,0663,3853,629
Inventory, net of allowances, customer advances and progress billings3,4373,220608492280504
Inventory3,4373,220608492280504
Prepaid expense17015216594130123
Other current assets113144102105279347
Other undisclosed current assets2774823096871,3511,193
Total current assets:11,33213,17014,2429,3818,6088,995
Noncurrent Assets
Operating lease, right-of-use asset1,8314114361,252
Property, plant and equipment11919384110201471
Intangible assets, net (including goodwill)2,6289,728    
Goodwill3484,528    
Intangible assets, net (excluding goodwill)2,2805,200    
Other noncurrent assets489476476477552613
Total noncurrent assets:5,06710,8089961,8397531,084
TOTAL ASSETS:16,39923,97815,23811,2209,36110,079
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,8043,1372,4172,1093,8062,138
Accounts payable1,0801,045302331551466
Accrued liabilities2,7242,0922,1151,7783,2551,672
Deferred revenue 4  434
Debt 105 2,339  
Derivative instruments and hedges, liabilities    3  
Deferred revenue and credits2,841
Contract with customer, liability2,398
Other undisclosed current liabilities449200416802(2,357) 
Total current liabilities:4,2573,4422,8335,6873,8474,979
Noncurrent Liabilities
Long-term debt and lease obligation:  24687505  
Liabilities, other than long-term debt1,588561  3821,017
Deferred revenue and credits802
Deferred rent credit     184
Other liabilities     198215
Operating lease, liability1,58824687505
Business combination, contingent consideration, liability  561    
Other undisclosed noncurrent liabilities  9,558(87)4,0551781,489
Total noncurrent liabilities:1,58810,365874,5605602,506
Total liabilities:5,84513,8072,92010,2474,4077,485
Equity
Equity, attributable to parent, including:10,55410,17112,3189734,9542,594
Preferred stock  680    
Common stock652478418279171154
Additional paid in capital165,081150,900147,963125,718119,764113,514
Accumulated deficit(158,152)(141,887)(136,063)(125,024)(114,981)(111,074)
Warrants and rights outstanding      1,489
Other undisclosed equity, attributable to parent2,973    (1,489)
Total equity:10,55410,17112,3189734,9542,594
TOTAL LIABILITIES AND EQUITY:16,39923,97815,23811,2209,36110,079

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues14,4048,4219,9346,59912,50818,230
Revenue, net18,230
Cost of revenue
(Cost of Goods and Services Sold)
(6,623)(2,776)(3,970)(1,738)(1,503)(2,784)
Gross profit:7,7815,6455,9644,86111,00515,446
Operating expenses(22,198)(14,507)(12,390) (18,876)(22,757)
Operating income (loss):(14,417)(8,862)(6,426)4,861(7,871)(7,311)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(276)(1,577)605 1912
Interest and debt expense    (18)  
Income (loss) from continuing operations before equity method investments, income taxes:(14,693)(10,439)(5,821)4,843(7,852)(7,299)
Other undisclosed income (loss) from continuing operations before income taxes4,0854,615(5,213)(14,495)1,311(101)
Loss from continuing operations before income taxes:(10,608)(5,824)(11,034)(9,652)(6,541)(7,400)
Income tax expense   (5) (4)(3)
Loss from continuing operations:(10,608)(5,824)(11,039)(9,652)(6,545)(7,403)
Loss before gain (loss) on sale of properties:(5,824)(11,039)(9,652)(6,545)(7,403)
Net loss:(10,608)(5,824)(11,039)(9,652)(6,545)(7,403)
Other undisclosed net loss attributable to parent    (6)  
Net loss attributable to parent:(10,608)(5,824)(11,039)(9,658)(6,545)(7,403)
Preferred stock dividends and other adjustments(5,657)(735) (829)  
Net loss available to common stockholders, basic:(16,265)(6,559)(11,039)(10,487)(6,545)(7,403)
Dilutive securities, effect on basic earnings per share    (1,311) 
Other undisclosed net income available to common stockholders, diluted      
Net loss available to common stockholders, diluted:(16,265)(6,559)(11,039)(10,487)(7,856)(7,403)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(10,608)(5,824)(11,039)(9,652)(6,545)(7,403)
Comprehensive loss, net of tax, attributable to parent:(10,608)(5,824)(11,039)(9,652)(6,545)(7,403)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: